Abstract: A compound of Formula (I) is provided that has been shown to be useful for treating a disease, disorder or syndrome that is mediated by the inhibition of mycolic acid biosynthesis through inhibition of M. tuberculosis Enoyl Acyl Carrier Protein Reductase enzyme (InhA): wherein R1, R2, R3, R4 and R5 are as defined herein.

Abstract: A compound of Formula (I) is provided that has been shown to be useful for treating a disease, disorder or syndrome that is mediated by the transportation of essential molecules in the mmpL3 pathway: wherein R1, R2, R3, R4, R5 and R6 are as defined herein.

Abstract: A processor system includes first and second regulators for regulating an adjusted supply voltage. In one embodiment, the regulator system comprises a digital low-dropout (DLDO) control system comprising first and second regulators that generate a plurality of control signals to regulate an adjusted power supply voltage and that generate a charge when a droop level falls below a droop threshold value. The first regulator implements a first control loop and the second regulator implements a second and much faster acting control loop. A supply adjustment block with the two regulators and control loops are provided for each processor core allowing different cores to have different regulated supply levels all based on one common supply.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.

Abstract: A compound of Formula (I) is provided that has been shown to be useful for treating a disease, disorder or syndrome that is mediated by the transportation of essential molecules in the mmpL3 pathway: wherein R1, R2, R3, R4, R5 and R6 are as defined herein.

Abstract: An endogenous source of magnetic resonance image contrast of biological tissues is provided by modeling a conventional magnetization transfer (CMT) spectrum using z-spectral data and generating magnetization transfer ratio maps from the magnetization transfer spectrum at a frequency of interest. A contribution by the CMT spectrum from the z-spectral data is removed and a direct water saturation component is modeled using the z-spectral data with removed CMT spectrum (z-spectral). When this modeled direct water saturation component contribution is removed from the z-spectral, then the remaining z-spectra reflects new contrast due to chemical exchange saturation transfer (CEST) and magnetization transfer/exchange effect from aliphatic protons probably associated with labile proteins, peptides and lipids, named as novel magnetization transfer (NMT).

Abstract: A magnetic resonance pulse sequence technique may acquire a water reference spectrum and two water suppressed metabolite spectra and with frequency selective inversion pulse centered at either single frequency, at multiple frequencies, or in a single acquisition. Subtraction of the inverted from non-inverted water suppressed metabolite spectrum results in single or a combination of specific metabolite peak/peaks alone with a flat baseline for easier quantification.

Abstract: A non-invasive imaging approach using CEST and MRS may be used to monitor the cleavage of the poly-L-glutamate (PLG) backbone. The cleavage of PLG by cathespsin B can expose exchangeable —NH2 protons in the PLG that are then monitored non-invasively through CEST. The technique can provide direct information on malignant tissue and tumor aggressiveness, and can also be used to monitor treatment.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.

Abstract: A compound of Formula (I) is provided that has been shown to be useful for treating a disease, disorder or syndrome that is mediated by the inhibition of mycolic acid biosynthesis through inhibition of M. tuberculosis Enoyl Acyl Carrier Protein Reductase enzyme (InhA): wherein R1, R2, R3, R4 and R5 are as defined herein.

Abstract: CEST imaging technique and MR scanning are used as an MRI method for measuring glutaminase mediated tumors. The method takes advantage of the fact that glutamine does not exhibit a significant Chemical Exchange Saturation Transfer (CEST) effect while glutamate does. In accordance with this method, one first obtains a glutamate CEST MRI map of the area of a tumor. L-glutamine (nontoxic up to several millimolar level) or glutaminase blocker is then injected and a post injection Glutamate CEST map is obtained. The difference in the spatial maps indicates the level of expression of glutaminase in the tumor.

Abstract: A compound of Formula (I) is provided that has been shown to be useful for treating a disease, disorder or syndrome that is mediated by the transportation of essential molecules in the mmpL3 pathway: wherein R1, R2, R3, R4, R5 and R6 are as defined herein.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.

Abstract: CEST imaging technique and MR scanning are used as an MRI method for measuring glutaminase mediated tumors. The method takes advantage of the fact that glutamine does not exhibit a significant Chemical Exchange Saturation Transfer (CEST) effect while glutamate does. In accordance with this method, one first obtains a glutamate CEST MRI map of the area of a tumor. L-glutamine (nontoxic up to several millimolar level) or glutaminase blocker is then injected and a post injection Glutamate CEST map is obtained. The difference in the spatial maps indicates the level of expression of glutaminase in the tumor.

Abstract: A customization program for use in customizing a baseboard management controller used for monitoring operation of various computer system components is disclosed. A user interacts with the customization program to customize the baseboard management controller based on a configuration of components specified for the baseboard of the computer system. The customization program provides a user interface having a repository of icons and a design page. The icons represent various components that may be connected, either directly or indirectly, to the baseboard. The design page is used for constructing a model representing the specified configuration of components. As a user drags icons onto the design page, the model is updated to reflect selection of the components corresponding to these icons. Further, the customization program creates a configuration file that identifies and describes each of the selected components.

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.

Abstract: The CEST effect for various neurotransmitters and energy metabolites in the brain and muscles and various endogenous metabolites in the liver, brain, and myocardium are imaged using MR imaging to illustrate a unique CEST effect that may be used to monitor the concentration of the metabolite and hence to characterize and monitor various disease states in the body correlated to the concentration of that metabolite. By adjusting the timing, amplitude, and length of the RF pulse as well as other parameters of the CEST pulse sequence to address the unique chemical shifts and exchange rates of the target, new targets with unique characteristics may be acquired using CEST MR imaging.

Abstract: Prior approaches have delivered 17O2 to a subject by inhalation, but the relationship between local signal changes and metabolism has been complicated by H217O created in non-cerebral tissues. During a brief pulse of 17O2 inhalation, this arterial input function for H217O is negligible due to convective transport delays. Additional delays in the arterial input function due to restricted diffusion of water makes pulsed inhalation of 17O2 even more effective. Accordingly, ventilator system are provided to deliver 17O2 as a brief pulse to a subject. Subsequent MR imaging demonstrates delayed appearance of H217O in the cerebral ventricles, suggesting that the arterial input function of H217O is delayed by restricted water diffusion in addition to convective transit delays. Delivery as a brief pulse therefore offers significant advantages in relating MR signal changes directly to metabolism.

Abstract: Methods of, and systems for, magnetic resonance imaging of diagnostic mapping of tissues, where sodium mapping is performed individually, as well as in combination with other images of tissue, such as T1?, T2, and/or T1-weighted images. In one method embodiment, a sodium image of the tissue is acquired during the same scanning session. Maps are constructed of each of the first and sodium images individually, and in combination, and further facilitate viewing in combination with each other as a single, blended image of the tissue. Maps of the images may be displayed individually or in combination with each other.